Translational gastroenterology and hepatology 2017
The big, the bad, and the exon 11: adjuvant imatinib for all gastro-intestinal stromal tumors or just the ugly?
Related Questions
Data suggest patients with D842V-mutated or KIT/PDGFRA WT GIST do not respond to imatinib, but NCCN guidelines does not take into consideration mutati...
New answer by Medical Oncologist at Rutgers Cancer Institute of New Jersey (August 4, 2020)
In my opinion, there is no role for adjuvant imatinib in this population for a number of reasons. First of all, "WT" GIST usually has a very good prognosis. "The median diseas...